XBIO REPORT

Tag: COVID-19

September 2, 2026

Updated COVID-19 Protection: FDA Approves New Pfizer-BioNTech Comirnaty Vaccine

NYSE: $PFE A New Development in COVID-19 Prevention As we continue to navigate the evolving landscape of respiratory health, the U.S. Food and Drug Administration (FDA) has taken a significant step forward. Pfizer and BioNTech have officially received FDA approval for their updated Comirnaty COVID-19 vaccine, specifically adapted to target more recent circulating variants. What…

FDA Acceptance

$PFE, BioNTech, COVID-19, fda, FDA Approval, pfizer, Vaccine
September 1, 2026

Moderna Receives U.S. FDA Approval for Updated 2026-2027 Spikevax and mNEXSPIKE COVID-19 Vaccines

NASDAQ: $MRNA CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for… Source: Read More

FDA Acceptance

$MRNA, COVID-19, FDA Approval, mNEXSPIKE, Moderna, moderna-inc, Spikevax
June 2, 2026

A New Frontier in COVID-19 Prevention: Understanding Ensitrelvir (Xocova)

A Major Milestone in COVID-19 Treatment The landscape of COVID-19 management has officially shifted with the recent regulatory milestone concerning Xocova (ensitrelvir). As the first oral medication of its kind approved for post-exposure prophylaxis, this development offers a new layer of protection for those who have been exposed to the virus. What is Xocova? Xocova…

Announcements, FDA Acceptance

Antiviral, COVID-19, Ensitrelvir, fda, Xocova

Tag: COVID-19

Updated COVID-19 Protection: FDA Approves New Pfizer-BioNTech Comirnaty Vaccine

Moderna Receives U.S. FDA Approval for Updated 2026-2027 Spikevax and mNEXSPIKE COVID-19 Vaccines

A New Frontier in COVID-19 Prevention: Understanding Ensitrelvir (Xocova)